{"classes":[{"categories":[{"measurements":[{"groupId":"OG000","spread":"0.96","value":"-0.3"},{"groupId":"OG001","spread":"0.71","value":"0.3"}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"54"},{"groupId":"OG001","value":"8"}],"units":"Participants"}],"title":"Change at Day 7"},{"categories":[{"measurements":[{"groupId":"OG000","spread":"0.94","value":"-0.3"},{"groupId":"OG001","spread":"0.64","value":"-0.1"}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"52"},{"groupId":"OG001","value":"8"}],"units":"Participants"}],"title":"Change at Day 28"},{"categories":[{"measurements":[{"groupId":"OG000","spread":"0.79","value":"-0.3"},{"groupId":"OG001","spread":"0.46","value":"0.3"}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"52"},{"groupId":"OG001","value":"8"}],"units":"Participants"}],"title":"Change at Day 56"},{"categories":[{"measurements":[{"groupId":"OG000","spread":"0.87","value":"-0.3"},{"groupId":"OG001","spread":"0.53","value":"0.0"}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"46"},{"groupId":"OG001","value":"8"}],"units":"Participants"}],"title":"Change at Day 78"},{"categories":[{"measurements":[{"groupId":"OG000","spread":"0.93","value":"-0.3"},{"groupId":"OG001","spread":"0.53","value":"0.0"}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"49"},{"groupId":"OG001","value":"8"}],"units":"Participants"}],"title":"Change at Day 100"},{"categories":[{"measurements":[{"groupId":"OG000","spread":"1.06","value":"-0.3"},{"groupId":"OG001","spread":"0.53","value":"0.0"}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"40"},{"groupId":"OG001","value":"8"}],"units":"Participants"}],"title":"Change at Day 128"},{"categories":[{"measurements":[{"groupId":"OG000","spread":"0.90","value":"-0.4"},{"groupId":"OG001","spread":"0.93","value":"0.0"}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"36"},{"groupId":"OG001","value":"8"}],"units":"Participants"}],"title":"Change at Day 156"},{"categories":[{"measurements":[{"groupId":"OG000","spread":"1.06","value":"-0.3"},{"groupId":"OG001","spread":"0.46","value":"0.3"}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"39"},{"groupId":"OG001","value":"8"}],"units":"Participants"}],"title":"Change at Day 184"},{"categories":[{"measurements":[{"groupId":"OG000","spread":"0.97","value":"-0.2"},{"groupId":"OG001","spread":"0.63","value":"0.0"}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"33"},{"groupId":"OG001","value":"6"}],"units":"Participants"}],"title":"Change at Day 212"},{"categories":[{"measurements":[{"groupId":"OG000","spread":"0.86","value":"-0.3"},{"groupId":"OG001","spread":"0.00","value":"0.0"}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"31"},{"groupId":"OG001","value":"3"}],"units":"Participants"}],"title":"Change at Day 240"},{"categories":[{"measurements":[{"groupId":"OG000","spread":"0.93","value":"-0.5"},{"comment":"Here, 'NA' signifies that SD could not be calculated as only 1 participant was evaluated.","groupId":"OG001","spread":"NA","value":"0.0"}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"34"},{"groupId":"OG001","value":"1"}],"units":"Participants"}],"title":"Change at Day 268"},{"categories":[{"measurements":[{"groupId":"OG000","spread":"1.20","value":"-0.2"},{"groupId":"OG001","spread":"0.00","value":"0.0"}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"33"},{"groupId":"OG001","value":"2"}],"units":"Participants"}],"title":"Change at Day 296"},{"categories":[{"measurements":[{"groupId":"OG000","spread":"1.12","value":"-0.6"},{"comment":"Here, 'NA' signifies that SD could not be calculated as only 1 participant was analyzed.","groupId":"OG001","spread":"NA","value":"0.0"}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"13"},{"groupId":"OG001","value":"1"}],"units":"Participants"}],"title":"Change at Day 324"},{"categories":[{"measurements":[{"groupId":"OG000","spread":"1.21","value":"-0.9"}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"7"},{"groupId":"OG001","value":"0"}],"units":"Participants"}],"title":"Change at Day 352"},{"categories":[{"measurements":[{"groupId":"OG000","spread":"0.71","value":"-0.5"}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"2"},{"groupId":"OG001","value":"0"}],"units":"Participants"}],"title":"Change at Day 380"}],"denoms":[{"counts":[{"groupId":"OG000","value":"54"},{"groupId":"OG001","value":"8"}],"units":"Participants"}],"description":"PGIS was a single item to assess severity of pain on a 5-point verbal rating scale ranged from 1 (no pain) to 5 (very severe pain), where 1: none; 2: mild; 3: moderate; 4: severe; 5: very severe. A higher score indicated a more severe pain.","dispersionType":"Standard Deviation","groups":[{"description":"Participants received a conditioning regimen of cyclophosphamide 300 mg/m\\^2 IV infusion and fludarabine 30 mg/m\\^2 IV infusion daily for 3 days from Day -5 to Day -3. On Day 1, participants received recommended phase 2 dose (RP2D) dose of JNJ-68284528 0.75\\*10\\^6 CAR positive viable T cells/kg as IV infusion.","id":"OG000","title":"Phase 2 (US Population)"},{"description":"Participants received a conditioning regimen of cyclophosphamide 300 mg/m\\^2 IV infusion and fludarabine 30 mg/m\\^2 IV infusion daily for 3 days from Day -5 to Day -3. On Day 1, participants received RP2D dose of JNJ-68284528 0.75\\*10\\^6 CAR positive viable T cells/kg as IV infusion.","id":"OG001","title":"Phase 2 (Japan Population)"}],"paramType":"MEAN","populationDescription":"mITT analysis Set included all participants who received a JNJ-68284528 infusion at the targeted RP2D dose level. Here, N (number of participants analyzed) signifies participants who were evaluable for this outcome measure and \"n\" (number analyzed) signifies those participants who were evaluable for specified time points.","reportingStatus":"POSTED","timeFrame":"Baseline, Days 7, 28, 56, 78, 100, 128, 156, 184, 212, 240, 268, 296, 324, 352, 380","title":"Phase 2: Change From Baseline in Patient Global Impression of Severity (PGIS) Score at Days 7, 28, 56, 78, 100, 128, 156, 184, 212, 240, 268, 296, 324, 352, 380","type":"SECONDARY","unitOfMeasure":"Score on a scale"}